- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- calcitriol + docetaxel
- Drug
- Lead sponsor
- Novacea
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 11
- States / cities
- Berkeley, California • Vallejo, California • Denver, Colorado + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 9,283
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Relapsed or Refractory Multiple Myeloma, Previously Treated Amyloid Light-chain (AL) Amyloidosis
- Interventions
- JNJ-79635322
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 9
- States / cities
- Duarte, California • Irvine, California • San Francisco, California + 5 more
- Conditions
- Neoplasms, Solid Tumor, Breast Neoplasms, Triple-Negative, Squamous Cell Carcinoma of Skin, Melanoma, Head and Neck Neoplasms, Carcinoma, Squamous Cell, Carcinoma, Non-Small-Cell Lung
- Interventions
- N17350
- Biological
- Lead sponsor
- Onchilles Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 6
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 2 more
- Conditions
- Gastrointestinal Stromal Tumors (GIST), Neoplasms, Connective Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms by Histologic Type, Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasm, Digestive System Disease, Gastrointestinal Diseases
- Interventions
- THE-630
- Drug
- Lead sponsor
- Theseus Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Miami, Florida + 4 more
- Conditions
- Solid Tumor
- Interventions
- Larotrectinib, Pembrolizumab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2029
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Multiple Myeloma
- Interventions
- P-BCMA-101 CAR-T cells, Rimiducid
- Biological · Drug
- Lead sponsor
- Poseida Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 16
- States / cities
- Gilbert, Arizona • Davis, California • San Diego, California + 11 more
- Conditions
- Healthy Volunteers
- Interventions
- NoV Placebo-matching Saline, NoV GI.1/GII.4 Bivalent VLP Vaccine
- Biological
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 4,748 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Great Lakes, Illinois
- Conditions
- Postoperative Pain Management
- Interventions
- SKY0402, Placebo
- Drug
- Lead sponsor
- Pacira Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Solid Neoplasms
- Interventions
- Dazostinag, Pembrolizumab, Platinum, 5-fluorouracil
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 26
- States / cities
- La Jolla, California • Los Angeles, California • Orange, California + 20 more
- Conditions
- Leukemia
- Interventions
- Patient-derived CD22-specific CAR T-cells also expressing an EGFRt
- Biological
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 1 Year to 26 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Inflammatory Bowel Disease
- Interventions
- Bone Marrow Stromal Cell (BMSC) Infusion
- Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Osteoporosis, Osteopenia
- Interventions
- Fiber Pill, Melatonin, Strontium citrate, Vitamins D3 and K2
- Dietary Supplement
- Lead sponsor
- Duquesne University
- Other
- Eligibility
- Female only
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC)
- Interventions
- pembrolizumab, placebo, cisplatin, 5-FU, radiotherapy, leucovorin, levoleucovorin, oxaliplatin
- Biological · Drug · Radiation
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 703 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 19
- States / cities
- Long Beach, California • Columbus, Georgia • Westwood, Kansas + 16 more
- Conditions
- Healthy Subjects
- Interventions
- STP707
- Drug
- Lead sponsor
- Sirnaomics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Healthy
- Interventions
- MBX 2109 (Part A), MBX 2109 (Part B), Placebo
- Drug
- Lead sponsor
- MBX Biosciences
- Industry
- Eligibility
- 21 Years to 60 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Dallas, Texas • Madison, Wisconsin
- Conditions
- Healthy
- Interventions
- bazedoxifene, bazedoxifene/conjugated estrogens
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 45 Years to 64 Years · Female only
- Enrollment
- 2 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Neoplasm
- Interventions
- Isatuximab SAR650984, Atezolizumab
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 3
- States / cities
- Santa Monica, California • Boston, Massachusetts • Houston, Texas
- Conditions
- Locally Advanced Intrahepatic Cholangiocarcinoma, Oligometastatic Intrahepatic Cholangiocarcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Intrahepatic Cholangiocarcinoma
- Interventions
- Angiography, Biopsy, Biospecimen Collection, Computed Tomography, Durvalumab, Magnetic Resonance Imaging, Positron Emission Tomography, Tremelimumab, Yttrium-90 Microsphere Radioembolization
- Procedure · Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Healthy Subjects
- Interventions
- TAVO103A, Placebo
- Drug · Other
- Lead sponsor
- Tavotek Biotherapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Healthy Volunteers
- Interventions
- Dupilumab coformulated with berahyaluronidase alfa, Dupilumab
- Biological
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Hialeah, Florida
- Conditions
- Neoplasms
- Interventions
- PF-04217903
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Chicago, Illinois • Boston, Massachusetts + 1 more
- Conditions
- Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Pancreatic Ductal, Tumor Virus Infections
- Interventions
- CC-486, Carboplatin, ABI-007
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • San Francisco, California • Indianapolis, Indiana + 4 more
- Conditions
- Complex Regional Pain Syndrome Type I
- Interventions
- Neridronate, Placebo
- Drug
- Lead sponsor
- Ambros Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 35
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 32 more
- Conditions
- Advanced Solid Tumor
- Interventions
- NB003 tablets
- Drug
- Lead sponsor
- Ningbo Newbay Technology Development Co., Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 6
- States / cities
- Stanford, California • Jacksonville, Florida • Boston, Massachusetts + 3 more